On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Innovations within the market, such as automatic insulin regulation tailored to individual ... the market faces potential challenges from the development of alternative insulin delivery methods and ...

High-rolling investors have positioned themselves bullish on DexCom (NASDAQ:DXCM), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom DXCM revealed 33 unusual trades. Delving into the details, we found 33% of traders were ...

LICOM's collaborations include the development of microfluidic-based high-throughput screening and the manufacture of medical devices such as insulin ... and other drug delivery systems.

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Luna is the first automated insulin delivery solution intended for the >90% of all people with insulin-requiring diabetes who take their insulin with an insulin pen, commonly called multiple daily ...